Jazz Pharmaceuticals, a global biopharmaceutical company, completed the acquisition of GW Pharmaceuticals, a British pharmaceutical company known for its multiple sclerosis treatment product nabiximols, for $7.2bn. "Over the last two decades, GW has built an unparalleled global leadership position in cannabinoid science, including the successful launch of Epidiolex, a breakthrough product within the field of epilepsy, and a diverse and robust neuroscience pipeline. We believe that Jazz is an ideal growth partner that is committed to supporting our commercial efforts, as well as ongoing clinical and research programs," Justin Gover, GW Pharmaceuticals CEO.